Company intelligence / Profile preview
Anhui Zhifei Longcom Biopharmaceutical
Hefei, Anhui, Chinaen.zhifeishengwu.com ↗
- Ownership
- Private
- Employees
- ~4500
- Development stage
- Other
01
Overview
Thirteen products launched as of mid–2024 including recombinant COVID‑19 vaccine (CHO cell), pneumococcal vaccines, meningococcal vaccines, influenza vaccines; pipeline includes next-generation norovirus and TB vaccines with positive early clinical data for safety/immunogenicity in multiple age groups.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant proteinGenetically engineered subunit vaccine
- Industry
- Pharma
02
Drug pipeline
22 assets21 more assets in the full pipeline.
03
Partnerships
Distribution partnerships with Merck Sharp & Dohme for HPV/Rota/Pneumovax/Hepatitis A vaccines
Beyond the preview
Go deeper on Anhui Zhifei Longcom Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anhui Zhifei Longcom Biopharmaceutical.